GT Biologics Ltd

GT Biologics Limited is a biotechnology company spun-out from the Rowett Institute, University of Aberdeen developeing novel products for treating gut disorders.

GT Biologics Logo

The company exploits the intellectual property of its founder Professor Denise Kelly and develops new therapies for the prevention and treatment of inflammatory diseases of the human gastrointestinal tract, including Crohn’s disease and Ulcerative colitis.

These include an oral-based probiotic product for the treatment of mild to moderate Crohn’s disease and ulcerative colitis and a novel family of protein/peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases.

The novel drug products have been derived from bacteria that naturally colonised the gut of healthy individuals and have been scientifically proven to exhibit potent anti-infectious and anti-inflammatory properties. Human gut bacteria provide a diverse and rich source of natural drugs and the company aims to use this novel platform for further drug discovery and product development.


Institute of Medical Sciences
AB25 2ZD